Jefferies Financial Group Inc. Invests $6.79 Million in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Jefferies Financial Group Inc. acquired a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 350,029 shares of the company's stock, valued at approximately $6,787,000. Jefferies Financial Group Inc. owned about 1.00% of Oruka Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $144,000. Geode Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $343,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $303,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Performance

NASDAQ ORKA traded up $0.60 on Friday, hitting $10.06. 92,459 shares of the stock were exchanged, compared to its average volume of 228,144. The stock has a fifty day moving average price of $9.86 and a two-hundred day moving average price of $14.77. The firm has a market capitalization of $376.66 million, a P/E ratio of -1.61 and a beta of 0.25. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. Sell-side analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ORKA shares. Wedbush reissued an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.